Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|April 5, 2018

AGC Biologics to Add New Facilities at Headquarters

The contract development and manufacturing organization announced the addition of a new building complex that will house its headquarters in Bothell, WA.

On March 29, 2018, AGC Biologics, a contract development and manufacturing organization specializing in the clinical and commercial manufacture of therapeutic proteins, announced plans of a new building complex that will house the company’s headquarters in Bothell, WA.

The new 150,000-square-foot complex is located adjacent to the existing AGC Biologics facility in Bothell. The complex will hold the company’s process development labs and corporate administrative offices and will provide expansion space for additional manufacturing capacity.

According to AGC Biologics, the new facilities allow the company to continue its expansion in the United States and will include a new R&D center dedicated to novel manufacturing technologies for faster development of therapeutic proteins.

“These new state-of-the-art facilities will enable us to meaningfully advance and further integrate the development, manufacturing, and commercial functions within our dynamic global headquarters, as well as provide additional footprint for further manufacturing expansion,” said Gustavo Mahler, president and CEO of AGC Biologics, in a company press release.

In March 2018, the company announced the addition of a 2000-L single-use bioreactor to its Berkeley, CA, facility to support its biologics capacity. AGC Biologics is a recent integration of Asahi Glass Company (AGC) Bioscience, a glass and chemical producer under AGC, Biomeva, a contract manufacturing organization, and CMC Biologics, a contract biologics manufacturer, which was announced in January 2018.

Source: AGC Biologics

Related to this article

View more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more